本帖最后由 老马 于 2013-3-13 13:43 编辑
0 ^/ |9 U/ j. w9 I3 |3 B8 u" u) E* k8 q
健择（吉西他滨）+顺铂+阿瓦斯汀
. l) ]/ I5 g, x: r' w Gemzar +Cisplatin + Avastin$ i, I6 w' Q% r: n: |' I. e
http://annonc.oxfordjournals.org/content/21/9/1804.full2 ~# d6 h( e2 |$ D- k$ f
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
) L8 n) `/ @+ g$ V# l- l) g( m$ q/ NPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
4 I$ t* u% u) X( QResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. / O& S! \9 }% n7 G
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 627)
" Z- a f5 _& [6 Y0 e, ]
华为网盘附件：; d: ` u) L& u" l3 X" t% P
【华为网盘】ava.JPG
/ L5 P/ u( R$ S% H2 V/ j+ q |
显身卡
